Healthcare is unlikely to be a defining issue in the upcoming US elections, giving investors hope that a second Trump presidency would not drive stock prices down, Bellevue Healthcare trust (BBH) manager Paul Major has said.
Speaking during a roundtable event in London last week, Major said Trump would likely take a softer stance on antitrust regulation, allowing for more mergers and acquisitions in the healthcare sector, and has refused to argue in favour of curtailing entitlement programmes. "Under a Trump presidency, there could be more excitement and appetite for M&A activity involving potential targets among small or mid-cap biotechs and healthcare programmes," he said. "This could drive out performance in this segment relative to large or mega-cap companies." Despite this, the Bellevue fund manager ...
To continue reading this article...
Join Investment Week for free
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes